Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

NCT00841971

Mycoses Fungemia Central Nervous System Fungal Infections +1 more

COMPLETED PHASE4

A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis

NCT01176058

Candidemia

TERMINATED PHASE3

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

NCT00095316

Candidiasis

TERMINATED PHASE3

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017

Aspergillosis Candidemia

COMPLETED PHASE4

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

NCT00036179

Candidiasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All subjects that have been treated with Anidulafungin according to its licence during the period of July 2009 and September 2010 will be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anidulafungin

anidulafungin

Intervention Type DRUG

A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anidulafungin

A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ECALTA, ERAXIS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who have been prescribed anidulafungin between 1st July 2009 and 30th September 2010.

Patients admitted to specialist liver unit wards and the Liver Intensive Therapy Unit during this period

Exclusion Criteria

* Patients who participated in any interventional clinical trial during this episode of sepsis.

Patients who received anidulafungin for infection prophylaxis

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No